Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

G. Kris, Mark; B. Natale, Ronald; S. Herbst, Roy; J. Lynch, T.; Prager, Diane; P. Belani, Chandra; H. Schiller, Joan; Kelly, Karen; Spiridonidis, H.; Sandler, Alan; S. Albain, Kathy; Cella, David; Wolf, Michael; D. Averbuch, Steven; Ochs, Judith; Kay, Andrea

doi:10.1001/jama.290.16.2149

Public

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Published in JAMA • Oct 22, 2003

Authors:

Mark G. Kris

Ronald B. Natale

Roy S. Herbst

Abstract

CONTEXT: More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell ...

Subject

Gefitinib

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!